All Phenotypes Tg(Tyr-cre/ERT2)1Lru MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Braf^tm1Mmcm/Braf⁺ Pten^tm1Mro/Pten^tm1Mro Tg(Tyr-cre/ERT2)1Lru/0	B6.Cg-Braf^tm1Mmcm Tg(Tyr-cre/ERT2)1Lru Pten^tm1Mro	MGI:5447169
cn2	Braf^tm1Cpri/Braf^tm1Cpri Tg(Tyr-cre/ERT2)1Lru/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:3843341
cn3	Braf^tm1Rima/Braf⁺ Kras^tm4Tyj/Kras⁺ Tg(Tyr-cre/ERT2)1Lru/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:4458349
cn4	Braf^tm1Cpri/Braf^tm1Cpri Cdkn2a^tm1Rdp/Cdkn2a^tm1Rdp Tg(Tyr-cre/ERT2)1Lru/0	involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL	MGI:3843342
cn5	Nras^tm1Tyj/Nras⁺ Tg(Tyr-cre/ERT2)1Lru/0	involves: C57BL/6 * DBA/2	MGI:5755095
cn6	Braf^tm1Rima/Braf⁺ Tg(Tyr-cre/ERT2)1Lru/0	involves: C57BL/6 * DBA/2	MGI:4458350
cn7	Nras^tm1Tyj/Nras^tm1Tyj Tg(Tyr-cre/ERT2)1Lru/0	involves: C57BL/6 * DBA/2	MGI:5755094
cn8	Braf^tm1Rima/Braf⁺ Tg(GFP/KRAS2/ALPP)1Brn/0 Tg(Tyr-cre/ERT2)1Lru/0	involves: C57BL/6 * DBA/2 * FVB/N	MGI:4458351

Allelic Composition	Braf^tm1Mmcm/Braf⁺ Pten^tm1Mro/Pten^tm1Mro Tg(Tyr-cre/ERT2)1Lru/0
Genetic Background	B6.Cg-Braf^tm1Mmcm Tg(Tyr-cre/ERT2)1Lru Pten^tm1Mro

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braf^tm1Mmcm mutation (3 available); any Braf mutation (60 available)
Pten^tm1Mro mutation (1 available); any Pten mutation (88 available)
Tg(Tyr-cre/ERT2)1Lru mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:188523 )

• tamoxifen-treated mice must be euthanized between 40 and 70 days due to tumor load or ulceration

decreased tumor-free survival time ( J:188523 )

• in tamoxifen treated mice

neoplasm

increased cutaneous melanoma incidence ( J:188523 )

• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days

• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction

• however, no visceral metastasis is observed

• however, treatment with PLX4720 decreases tumor outgrowth

• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression

integument

spontaneous skin ulceration ( J:188523 )

• in tamoxifen-treated mice

increased cutaneous melanoma incidence ( J:188523 )

• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days

• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction

• however, no visceral metastasis is observed

• however, treatment with PLX4720 decreases tumor outgrowth

• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased skin tumor incidence ( J:147434 )

• tamoxifen-treated mice develop nevi most commonly at the site of application with some large melanocytic lesions around the perianal regions and in the eyelids unlike in control mice (either treated with only ethanol or lacking one of the alleles)

• nevi in tamoxifen-treated mice are slowly proliferating, dome-shaped outgrowths in the dermis composed of pigmented epithelioid or dendritic melanocytes with neuroid differentiation in some cases

• 80% of tamoxifen-treated mice develop eyelid nevi 3 to 5 months after treatment

• mice treated with high doses of tamoxifen develop perianal nevi 6 to 10 months after treatment

• 60% to 70% of tamoxifen-treated mice develop rapidly growing, invasive hypopigmented skin tumors that often (in 38% of mice) ulcerate the overlying epidermis, infiltrate the subcutis, skeletal muscle, and auricular cartilage and display characteristics of malignant melanomas

increased melanoma incidence ( J:147434 )

• some tamoxifen-treated mice develop oligomelanotic malignant melanomas unlike control mice (either treated with only ethanol or lacking one of the alleles)

• 54% of tamoxifen-treated mice develop melanomas within 12 months

• 64% of tamoxifen-treated mice develop melanomas after 14 months

• median latency to develop melanomas in a tamoxifen-treated mouse is 12 months

pigmentation

hyperpigmentation ( J:147434 )

• following application of tamoxifen on the back, snouts, tails, ears, and paws are visibly darkened compared to in control mice (either treated with only ethanol or lacking one of the alleles)

• following application of tamoxifen on the back, 40% of mice develop darkened toenails proximal to the body on the front or hind feet unlike control mice

• following application of tamoxifen on the back, 50% of females develop darkened nipples unlike control mice

• following application of tamoxifen on the back, hairy skin is darkened most noticeable at the site of application unlike control mice

integument

spontaneous skin ulceration ( J:147434 )

• in 38% of tamoxifen-treated mice

increased skin tumor incidence ( J:147434 )

• nevi in tamoxifen-treated mice are slowly proliferating, dome-shaped outgrowths in the dermis composed of pigmented epithelioid or dendritic melanocytes with neuroid differentiation in some cases

• 80% of tamoxifen-treated mice develop eyelid nevi 3 to 5 months after treatment

• mice treated with high doses of tamoxifen develop perianal nevi 6 to 10 months after treatment

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
melanoma		DOID:1909		J:147434

Allelic Composition	Braf^tm1Rima/Braf⁺ Kras^tm4Tyj/Kras⁺ Tg(Tyr-cre/ERT2)1Lru/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braf^tm1Rima mutation (0 available); any Braf mutation (60 available)
Kras^tm4Tyj mutation (9 available); any Kras mutation (84 available)
Tg(Tyr-cre/ERT2)1Lru mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased tumor incidence ( J:161180 )

• within 6 months, tamoxifen-treated mice develop large, rapid growing oligo-pigmented tumors with ulceration unlike wild-type mice

• tumors in tamoxifen-treated mice are largely composed of spindle cells with malignancy features

pigmentation

hyperpigmentation ( J:161180 )

• within 2 to 3 months, tamoxifen-treated mice exhibit a darkening of the tails, ears, and paws compared with wild-type mice

Allelic Composition	Braf^tm1Cpri/Braf^tm1Cpri Cdkn2a^tm1Rdp/Cdkn2a^tm1Rdp Tg(Tyr-cre/ERT2)1Lru/0
Genetic Background	involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braf^tm1Cpri mutation (0 available); any Braf mutation (60 available)
Cdkn2a^tm1Rdp mutation (6 available); any Cdkn2a mutation (67 available)
Tg(Tyr-cre/ERT2)1Lru mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:147434 )

• tamoxifen-treated mice develop multiple tumors unlike Braf^tm1Cpri/Braf^tm1Cpri Tg(Tyr-cre/ERT2)1Laru mice that develop single tumors

increased skin tumor incidence ( J:147434 )

• tamoxifen-treated mice develop nevi unlike control mice (either treated with only ethanol or lacking one of the alleles)

increased melanoma incidence ( J:147434 )

• 80% of tamoxifen-treated mice develop melanomas within 12 months

• median latency to develop melanomas in a tamoxifen-treated mouse is 7 months

integument

increased skin tumor incidence ( J:147434 )

• tamoxifen-treated mice develop nevi unlike control mice (either treated with only ethanol or lacking one of the alleles)

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:147434 )

• tamoxifen-treated mice develop multiple tumors unlike Braf^tm1Cpri/Braf^tm1Cpri Tg(Tyr-cre/ERT2)1Laru mice that develop single tumors

Allelic Composition	Nras^tm1Tyj/Nras⁺ Tg(Tyr-cre/ERT2)1Lru/0
Genetic Background	involves: C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nras^tm1Tyj mutation (1 available); any Nras mutation (44 available)
Tg(Tyr-cre/ERT2)1Lru mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

integument

abnormal skin morphology ( J:198244 )

• mice painted with tamoxifen on to shaven back skin develop small paucicelluar nevi in the deep dermal and periadnexal regions of the skin

pigmentation

hyperpigmentation ( J:198244 )

• 50% of mice painted with tamoxifen on to shaven back skin at about 2 months of age exhibit weak darkening of the skin within 4 to 8 months

Allelic Composition	Braf^tm1Rima/Braf⁺ Tg(Tyr-cre/ERT2)1Lru/0
Genetic Background	involves: C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braf^tm1Rima mutation (0 available); any Braf mutation (60 available)
Tg(Tyr-cre/ERT2)1Lru mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

pigmentation

pigmentation phenotype ( J:161180 )

N	• mice exhibit normal pigmentation and do not develop nevi

neoplasm

neoplasm ( J:161180 )

N	• mice do not develop tumors

Allelic Composition	Nras^tm1Tyj/Nras^tm1Tyj Tg(Tyr-cre/ERT2)1Lru/0
Genetic Background	involves: C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nras^tm1Tyj mutation (1 available); any Nras mutation (44 available)
Tg(Tyr-cre/ERT2)1Lru mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

integument

abnormal skin morphology ( J:198244 )

• mice painted with tamoxifen on to shaven back skin develop large multicellular nevi in the deep dermal and periadnexal regions of the skin

pigmentation

hyperpigmentation ( J:198244 )

• mice painted with tamoxifen on to shaven back skin at about 2 months of age exhibit darkening of the skin within 4 to 8 months; darkening is more apparent in tamoxifen-treated areas but systemic effects are seen with darkening of the tails

neoplasm

neoplasm ( J:198244 )

N	• tamoxifen painted mice do not develop cutaneous melanoma, even after 24 months of tamoxifen-induced expression

Allelic Composition	Braf^tm1Rima/Braf⁺ Tg(GFP/KRAS2/ALPP)1Brn/0 Tg(Tyr-cre/ERT2)1Lru/0
Genetic Background	involves: C57BL/6 * DBA/2 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braf^tm1Rima mutation (0 available); any Braf mutation (60 available)
Tg(GFP/KRAS2/ALPP)1Brn mutation (1 available)
Tg(Tyr-cre/ERT2)1Lru mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased melanoma incidence ( J:161180 )

• tamoxifen-treated mice exhibit rapid onset of melanoma with a median onset at 2 months and 100% penetrance within 3 months

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 12/10/2024 MGI 6.24